Dare Bioscience, Inc.
Daré Bioscience, Inc. (Nasdaq: DARE) is a health biotechnology company focused on developing and commercializing products for women’s health, including contraception, sexual health, menopause, pelvic pain, fertility, vaginal health and infectious disease. It pursues FDA approval for product candidates, Section 503B… From the company’s description.
Over the twelve months to Jun 30, 2026, Dare Bioscience, Inc. reported revenue of $1.37M and a net loss of $10.99M. Its operating margin was −813.3%, and operations used $11.29M in cash. In fiscal 2025, it reported revenue of $1.03M, up 10429.4% from fiscal 2024, and a net loss of $13.40M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Dare Bioscience, Inc. does
In the company’s own words
Daré Bioscience, Inc. (Nasdaq: DARE) is a health biotechnology company focused on developing and commercializing products for women’s health, including contraception, sexual health, menopause, pelvic pain, fertility, vaginal health and infectious disease. It pursues FDA approval for product candidates, Section 503B compounding for selected prescription products, and consumer health products that do not require prescriptions. Its offerings include DARE to PLAY sildenafil cream, a compounded prescription product launched in December 2025; the planned DARE to RESTORE vaginal probiotic line, beginning with Flora Sync LF5; and its pipeline candidate Ovaprene, a hormone-free monthly contraceptive in a pivotal Phase 3 study. Daré also licenses worldwide development, manufacturing and commercialization rights to XACIATO, an FDA-approved vaginal gel for bacterial vaginosis, to Organon. The company relies on collaborators and third parties for manufacturing, dispensing, logistics and commercialization rather than maintaining its own sales and distribution infrastructure. Daré began assembling its portfolio in 2017 through acquisitions, licenses and collaborations. Its website is www.darebioscience.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1401914
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Dare Bioscience, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Dare Bioscience, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Dare Bioscience, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Dare Bioscience, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Dare Bioscience, Inc.'s last four quarterly filings that the numbers alone won't show?”